HGS To Focus On "Core Pipeline" As Part Of Cost Reduction Plan; CEO Steps Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Human Genome Sciences plans to reduce its headcount by 20% and limit the number of drugs in early development. In 2004 and 2005, the company will focus on five products in immunology/infectious disease and oncology.